Perceptive Informatics Strengthens Cardiac Capabilities
Perceptive Informatics (Boston, MA) is expanding its imaging capabilities for cardiology trials with the addition of nuclear imaging technology from Hermes Medical Solutions (Stockholm, Sweden) and INVIA (Ann Arbor, MI).
"Key goals in expanding our capabilities with this advanced nuclear imaging functionality are to help customers make earlier safety and efficacy assessments and better decisions about their compounds in order to bring new cardiovascular treatments to patients sooner,” said Kenneth G. Faulkner, PhD, Perceptive's Vice President of Medical Imaging, in a press release.
By incorporating components of Hermes Medical Solutions' Nuclear Medicine Software Suite and INVIA's Corridor4DM, Perceptive says it will enhance the electronic processing, review, analysis, reporting, and archiving of images for cardiology trials.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
